In three distinct GEP datasets (23, 24, 25), we also observed that AML patients with FADS1 expression above the median display significantly lower survival rates than those with FADS1 levels below the median (Fig. 1F). This evidence concerns the gene FADS1 and acute myeloid leukemia.